Welcome to our dedicated page for Vincerx Pharma news (Ticker: VINC), a resource for investors and traders seeking the latest updates and insights on Vincerx Pharma stock.
Vincerx Pharma reports company developments centered on its wind-down activities, proposed liquidation and dissolution, and related stockholder voting matters. Recent updates have covered special meeting adjournments, proxy solicitation for the dissolution proposal, potential liquidating distributions, and the effect of continuing operating costs on available cash.
The company’s news also includes corporate-status developments such as the move from Nasdaq trading to OTC Pink quotation, intentions to deregister with the SEC, terminated strategic transaction discussions, and efforts to monetize assets or pursue out-licensing opportunities tied to its former oncology drug-development activities.
Vincerx Pharma (VINC) announced cost-control measures and strategic alternatives exploration to support its Phase 1 study of VIP943, a CD123-targeted antibody-drug conjugate. The clinical trial has shown promising results, with one acute myeloid leukemia patient achieving CRi and one high-risk myelodysplastic syndrome patient achieving CRL out of nine evaluable patients. The company will implement a 55% workforce reduction to focus resources on VIP943's advancement.
Strategic options under consideration include out-licensing, mergers and acquisitions, reverse mergers, and asset sales. The company reported approximately $8.4 million in cash, cash equivalents, and marketable securities as of October 31, 2024. Additional cohort results are expected by early Q1 2025.
Vincerx Pharma reported Q3 2024 financial results and clinical program updates. The company continues enrollment in Phase 1 study of VIP943, showing promising results with two complete responses in AML and MDS patients. Cash position stands at $10.1M as of September 30, 2024, expected to last into early 2025. Q3 net loss was $7.8M ($0.17 per share), compared to $9.0M ($0.42 per share) in Q3 2023. R&D expenses decreased to $3.9M from $6.1M year-over-year, while G&A expenses increased slightly to $3.9M from $3.5M.
Vincerx Pharma (Nasdaq: VINC) reported positive initial clinical data from its ongoing VIP943 Phase 1 dose-escalation study in relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and B-cell acute lymphoblastic leukemia (B-ALL). The study has enrolled 22 patients to date, with two complete responses observed so far. VIP943 has shown favorable safety and tolerability, with no dose-limiting toxicities reported.
The company also provided updates on its VIP236 and enitociclib programs. VIP236 showed promising monotherapy duration of response in advanced cancer patients, while enitociclib demonstrated a 57% overall response rate in a Phase 1 study for relapsed/refractory lymphoma. Vincerx is focusing its resources on the continued development of VIP943 and expects its cash runway to extend into early 2025.
Vincerx Pharma (Nasdaq: VINC) reported Q2 2024 financial results and provided clinical program updates. Key highlights include:
1. Ongoing enrollment in Phase 1 studies for VIP943 (ADC) and VIP236 (SMDC), with data expected by Q4 and Q3 2024, respectively.
2. Cash position of $16.3 million as of June 30, 2024, expected to fund operations through 2024.
3. Q2 2024 net loss of $1.8 million ($0.05 per share), compared to $11.6 million ($0.54 per share) in Q2 2023.
4. R&D expenses decreased to $3.8 million from $8.2 million year-over-year.
5. G&A expenses slightly decreased to $3.6 million from $3.8 million year-over-year.
Vincerx Pharma (Nasdaq: VINC) reported Q1 2024 financial results and provided a corporate update. Key highlights include progress in Phase 1 dose-escalation studies for VIP943 and VIP236, and positive results from enitociclib in clinical trials. The company secured financing to support operations through 2024, with $5.1 million in cash as of March 31, 2024, plus $17.8 million from recent financing. Research and development expenses decreased to $4.6 million from $10.9 million YoY, while general and administrative expenses dropped to $2.9 million from $4.5 million YoY. The net loss narrowed to $12.4 million or $0.58 per share, from $14.6 million or $0.69 per share in Q1 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.